Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?
Twist Bioscience (TWST) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.59 per share a year ago.
Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.
| Professional Services Industry | Industrials Sector | Emily Marine Leproust CEO | NASDAQ (NGS) Exchange | 90184D100 CUSIP |
| US Country | 923 Employees | - Last Dividend | - Last Split | 31 Oct 2018 IPO Date |
Twist Bioscience Corporation is a pioneering entity in the biotechnology sector, focusing on the creation and commercialization of synthetic DNA-based products. Founded in 2013 with its headquarters in South San Francisco, California, the company serves a broad spectrum of fields including therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research. By catering to biotech, pharmaceutical, industrial chemical, and agricultural companies, as well as academic laboratories, Twist Bioscience addresses the growing demand for synthetic genes, gene fragments, and other molecular biology tools essential for innovation and research across these industries.
The range of products and services offered by Twist Bioscience includes: